



1. Company details

Name of entity:	DorsaVi Limited and controlled entities
ABN:	15 129 742 409
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

2. Results for announcement to the market

			\$
Revenues from ordinary activities	down	13.9% to	1,148,959
Loss from ordinary activities after tax attributable to the owners of DorsaVi Limited and controlled entities	up	21.7% to	(1,517,753)
Loss for the year attributable to the owners of DorsaVi Limited and controlled entities	up	21.7% to	(1,517,753)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

Financial Performance

During the financial year, the consolidated entity generated \$1,129,493 in sales revenue compared to \$1,304,238 in the previous financial year.

The loss for the Group consisting of dorsaVi and the entities it controlled after providing for income tax amounted to \$1,517,753 (30 June 2024: \$1,247,582). The majority of the costs during the year remained consistent with the previous financial year.

Financial Position

During the financial year, the consolidated entity increased its net assets by \$1,812,306 to \$2,835,656 (30 June 2024: \$1,023,350). The main increase in the net assets of the consolidated entity resulted from capital raisings completed during the financial year.

All other items in the Statement of Financial Position remained consistent with the previous financial year.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	0.30	0.16

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

DorsaVi Limited and controlled entities
Appendix 4E
Preliminary final report

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

The consolidated entity has been consolidated in accordance with the Australian Accounting Standards and Interpretations issued by the Australian Accounting Standard Board and the Corporations Act. They also comply with the International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

This report, and the accompanying preliminary final report, are based upon accounts which are in the process of being audited.

11. Attachments

Details of attachments (if any):

The unaudited summary consolidated preliminary final report for dorsaVi Limited and its controlled entities for the year ended 30 June 2025 are attached.

12. Signed

Signed



Date: 29 August 2025

Gernot Abl
Non-executive Chairman

DorsaVi Limited and controlled entities
Contents
30 June 2025

Corporate directory	1
Statement of profit or loss and other comprehensive income	2
Statement of financial position	3
Statement of changes in equity	4
Statement of cash flows	5
Notes to the financial statements	6

DorsaVi Limited and controlled entities**Corporate directory****30 June 2025**

Directors	Gernot Abl (Non-Executive Chairman) Andrew Ronchi (Chief Executive Officer and Executive Director) Vineet Agarwal (Non-Executive Chairman) Leigh Travers (Non-Executive Director)
Company secretary	Justin Mouchacca
Registered office	C/- JM Corporate Services Suite 1, Level 6 350 Collins Street Melbourne, VIC 3000 Phone: (03) 8630 3321
Principal place of business	Unit 3, 11-13 Milgate Street, Oakleigh South, VIC 3167 Tel: 1800 367 728
Share register	Computershare Investor Services Pty Limited GPO Box 2975, Melbourne, VIC 3001 Tel: + 61 3 9415 4062
Auditor	MVAB Assurance Level 5, North Tower, 485 LaTrobe Street Melbourne, VIC 3008 Tel: +61 3 9642 8000
Stock exchange listing	DorsaVi Limited and controlled entities shares are listed on the Australian Securities Exchange (ASX code: DVL)
Website	https://www.dorsavi.com/

DorsaVi Limited and controlled entities
Statement of profit or loss and other comprehensive income
For the year ended 30 June 2025

	Note	2025 \$	2024 \$
Revenue and other income			
Sales revenue	2	1,129,493	1,304,238
Other income	2	19,466	30,803
		<u>1,148,959</u>	<u>1,335,041</u>
Expenses			
Cost of sales	3	(157,670)	(123,486)
Advertising expenses		(73,967)	(61,332)
Consultancy expenses		(313,568)	(344,749)
Depreciation and amortisation expense	3	(62,020)	(78,952)
Employee benefits expenses	3	(1,299,203)	(1,421,662)
Finance costs		(12,702)	(22,344)
Insurance expenses		(123,554)	(136,256)
Occupancy expenses		(18,867)	(8,036)
Professional fees		(461,723)	(383,557)
Software expenses		(190,665)	(214,669)
Travel expenses		(70,207)	(19,487)
Other expenses		<u>(238,671)</u>	<u>(224,613)</u>
Loss before income tax benefit		(1,873,858)	(1,704,102)
Income tax benefit		<u>356,105</u>	<u>456,520</u>
Loss after income tax benefit for the year attributable to the owners of DorsaVi Limited and controlled entities		(1,517,753)	(1,247,582)
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Exchange differences on translation of foreign subsidiaries net of tax		<u>(24,306)</u>	<u>(13,910)</u>
Other comprehensive income for the year, net of tax		<u>(24,306)</u>	<u>(13,910)</u>
Loss for the year		<u>(1,542,059)</u>	<u>(1,261,492)</u>
		Cents	Cents
Basic earnings per share	15	(0.22)	(0.23)
Diluted earnings per share	15	(0.22)	(0.23)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

DorsaVi Limited and controlled entities
Statement of financial position
As at 30 June 2025

	Note	2025 \$	2024 \$
Assets			
Current assets			
Cash and cash equivalents		2,293,549	478,100
Trade and other receivables	4	658,309	859,424
Inventories	5	430,563	489,567
Other assets	6	123,365	133,338
Total current assets		<u>3,505,786</u>	<u>1,960,429</u>
Non-current assets			
Property, plant and equipment		145,460	206,326
Intangibles assets	7	320,149	17,309
Total non-current assets		<u>465,609</u>	<u>223,635</u>
Total assets		<u>3,971,395</u>	<u>2,184,064</u>
Liabilities			
Current liabilities			
Trade and other payables	8	464,783	396,785
Borrowings		45,552	49,993
Lease liabilities		43,082	36,827
Provisions	9	236,905	181,724
Other liabilities	10	272,572	383,425
Total current liabilities		<u>1,062,894</u>	<u>1,048,754</u>
Non-current liabilities			
Lease liabilities		68,255	103,352
Provisions	9	4,590	8,608
Total non-current liabilities		<u>72,845</u>	<u>111,960</u>
Total liabilities		<u>1,135,739</u>	<u>1,160,714</u>
Net assets		<u>2,835,656</u>	<u>1,023,350</u>
Equity			
Issued capital	11	50,584,213	47,288,516
Reserves	12	93,158	266,870
Accumulated losses		<u>(47,841,715)</u>	<u>(46,532,036)</u>
Total equity		<u>2,835,656</u>	<u>1,023,350</u>

The above statement of financial position should be read in conjunction with the accompanying notes

DorsaVi Limited and controlled entities
Statement of changes in equity
For the year ended 30 June 2025

	Issued capital \$	Reserves \$	Retained profits \$	Total equity \$
Balance at 1 July 2023	46,325,268	637,844	(45,284,454)	1,678,658
Loss after income tax benefit for the year	-	-	(1,247,582)	(1,247,582)
Other comprehensive income for the year, net of tax	-	(13,910)	-	(13,910)
Total comprehensive income for the year	-	(13,910)	(1,247,582)	(1,261,492)
<i>Transactions with owners in their capacity as owners:</i>				
Contributions of equity, net of transaction costs (note 11)	470,000	-	-	470,000
Share-based payments	71,283	64,901	-	136,184
Transfer from share based payment reserve	421,965	(421,965)	-	-
Balance at 30 June 2024	<u>47,288,516</u>	<u>266,870</u>	<u>(46,532,036)</u>	<u>1,023,350</u>
	Issued capital \$	Reserves \$	Retained profits \$	Total equity \$
Balance at 1 July 2024	47,288,516	266,870	(46,532,036)	1,023,350
Loss after income tax benefit for the year	-	-	(1,517,753)	(1,517,753)
Other comprehensive income for the year, net of tax	-	(24,306)	-	(24,306)
Total comprehensive income for the year	-	(24,306)	(1,517,753)	(1,542,059)
<i>Transactions with owners in their capacity as owners:</i>				
Contributions of equity, net of transaction costs (note 11)	3,169,615	-	-	3,169,615
Share-based payments	126,082	58,668	-	184,750
Expiry of options	-	(208,074)	208,074	-
Balance at 30 June 2025	<u>50,584,213</u>	<u>93,158</u>	<u>(47,841,715)</u>	<u>2,835,656</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

DorsaVi Limited and controlled entities
Statement of cash flows
For the year ended 30 June 2025

	Note	2025 \$	2024 \$
Cash flows from operating activities			
Receipts from customers		1,129,493	1,408,990
Payments to suppliers and employees		(2,508,084)	(2,508,891)
Interest paid		(12,702)	(32,474)
Grants and sundry income received		-	22,000
Interest received		19,466	10,803
Income tax refunded		415,000	498,675
Net cash used in operating activities		(956,827)	(600,897)
Cash flows from investing activities			
Payments for property, plant and equipment		-	(3,226)
Payments for intangibles	7	(303,995)	(17,954)
Net cash used in investing activities		(303,995)	(21,180)
Cash flows from financing activities			
Proceeds from issue of shares	11	3,375,000	500,000
Cost of raising capital and issuing convertible note		(259,200)	(30,000)
Repayment of borrowings		-	(200,000)
Payment of principal portion lease liability		(39,529)	(42,944)
Net cash from financing activities		3,076,271	227,056
Net increase/(decrease) in cash and cash equivalents		1,815,449	(395,021)
Cash and cash equivalents at the beginning of the financial year		478,100	878,724
Effects of exchange rate changes on cash and cash equivalents		-	(5,603)
Cash and cash equivalents at the end of the financial year		<u>2,293,549</u>	<u>478,100</u>

The above statement of cash flows should be read in conjunction with the accompanying notes

DorsaVi Limited and controlled entities
Notes to the financial statements
30 June 2025

Note 1. General Information

The preliminary final report cover dorsaVi Limited as a consolidated entity consisting of dorsaVi Limited and the entities it controlled at the end of, or during, the year. The preliminary final report are presented in Australian dollars, which is dorsaVi Limited's functional and presentation currency.

dorsaVi Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

C/- JM Corporate Services
Suite 1, Level 6
350 Collins Street

Unit 3, 11-13 Milgate Street,
Oakleigh South, VIC 3167

Melbourne, VIC 3000

The preliminary final report were authorised for issue, in accordance with a resolution of directors, on 29 August 2025. The directors have the power to amend and reissue the preliminary final report.

Note 2. Revenue

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

	2025 \$	2024 \$
<i>Revenue recognised at a point in time:</i>		
Clinical income	219,187	102,131
Workplace income	143,672	169,576
	<u>362,859</u>	<u>271,707</u>
<i>Revenue recognised over time:</i>		
Clinical income	625,707	859,185
Workplace income	140,927	173,345
	<u>766,634</u>	<u>1,032,530</u>
<i>Revenue from contracts with customers is disclosed in the segment note as follows:</i>		
Clinical income	844,894	961,317
Workplace income	284,599	342,921
	<u>1,129,493</u>	<u>1,304,238</u>
Other income:	-	-
Grant and other income	-	20,000
Interest income	19,466	10,803
	<u>1,148,959</u>	<u>1,335,041</u>

DorsaVi Limited and controlled entities
Notes to the financial statements
30 June 2025

Note 3. Expenses

	2025	2024
	\$	\$
Loss before income tax includes the following specific expenses:		
<i>Depreciation and amortisation</i>		
Depreciation	20,243	39,175
Amortisation of patents and intangibles	41,777	39,777
Total depreciation	62,020	78,952
<i>Employee benefits expense</i>		
Share based payments	1,972	87,923
Other employee benefits	1,297,231	1,340,744
Total employee benefits expense	1,299,203	1,428,667
	1,361,223	1,507,619
Research and development expense	915,648	1,049,471
Cost of sales	157,670	123,486
Bad debts	11,692	16,204
	1,085,010	1,189,161

Note 4. Current assets - trade and other receivables

	2025	2024
	\$	\$
Receivables from contracts with customers	186,526	284,717
Less: Allowance for credit losses	(10,559)	(21,036)
	175,967	263,681
Contract assets	84,035	139,223
R&D tax offset refundable	398,307	456,520
	482,342	595,743
	658,309	859,424

Contract assets

The Group recovered the majority of the 2024 contract assets within the 2025 year and expects the 2025 balance to be settled within 12 months.

Note 4. Current assets - trade and other receivables (continued)

Credit losses:

The group applies the simplified approach under AASB 9 to measuring the allowance for credit losses for both receivables from contracts with customers and contract assets. Under the AASB 9 simplified approach, the group determines the allowance for credit losses for receivables from contracts with customers and contract assets on the basis of the lifetime expected credit losses of the instrument. Lifetime expected credit losses represent the expected credit losses that are expected to result from default events over the expected life of the financial asset.

The group determines expected credit losses using a provision matrix based on the group's historical credit loss experience, adjusted for factors that are specific to the financial asset as well as current and future expected economic conditions relevant to the financial asset. When material, the time value of money is incorporated into the measurement of expected credit losses. There has been no change in the estimation techniques or significant assumptions made during the reporting period.

Life-time expected credit losses - receivables from contracts with customers:

	2025	2024
	\$	\$
Opening balance	(21,036)	(11,918)
Net remeasurement of loss allowance	(1,214)	(25,322)
Amounts written off	11,690	16,204
	<u>11,690</u>	<u>16,204</u>
Closing balance	<u>(10,560)</u>	<u>(21,036)</u>

Allowance for expected credit losses

The ageing of the receivables and allowance for expected credit losses provided for above are as follows:

	Expected credit loss rate		Carrying amount		Allowance for expected credit losses	
	2025	2024	2025	2024	2025	2024
	%	%	\$	\$	\$	\$
Not overdue	-	0.02%	68,036	72,229	-	14
0 to 3 months overdue	-	1.08%	28,359	95,027	-	1,026
3 to 6 months overdue	-	0.25%	22,915	75,971	-	190
Over 6 months overdue	15.71%	47.72%	67,216	41,490	10,560	19,799
			<u>186,526</u>	<u>284,717</u>	<u>10,560</u>	<u>21,029</u>

Accounting policy for trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The Group consisting of dorsaVi and the entities it controlled has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Note 5. Current assets - inventories

	2025	2024
	\$	\$
Finished goods - at cost	<u>430,563</u>	<u>489,567</u>

DorsaVi Limited and controlled entities
Notes to the financial statements
30 June 2025

Note 5. Current assets - inventories (continued)

Accounting policy for inventories

Finished goods are stated at the lower of cost and net realisable value on a 'first in first out' basis. Cost comprises of purchase and delivery costs, net of rebates and discounts received or receivable.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Note 6. Current assets - other assets

	2025 \$	2024 \$
Prepayments and other assets	123,365	133,338

Note 7. Non-current assets - intangibles assets

	2025 \$	2024 \$
Patents - at cost	388,959	379,318
Less: Accumulated amortisation	(363,164)	(362,009)
	25,795	17,309
Development expenditure - at cost	5,261,956	5,261,956
Less: Accumulated amortisation and provision for impairment	(5,261,956)	(5,261,956)
	-	-
NTU Agreement - at cost	294,354	-
	320,149	17,309

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Patents \$	Total \$
Balance at 1 July 2023	-	-
Additions	17,954	17,954
Amortisation expense	(645)	(645)
Balance at 30 June 2024	17,309	17,309
Additions	303,995	303,995
Amortisation expense	(1,155)	(1,155)
Balance at 30 June 2025	320,149	320,149

Development expenditure incurred during the year ended 30 June 2025 has been fully expensed.

Note 7. Non-current assets - intangibles assets (continued)

Accounting policy for intangible assets

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

Patents and trademarks

Significant costs associated with patents and trademarks are deferred and amortised on a straight-line basis over the period of their expected benefit, being their finite life of 20 years.

Note 8. Current liabilities - trade and other payables

	2025	2024
	\$	\$
Trade payables	269,173	129,078
Sundry creditors and accruals	195,610	267,707
	<u>464,783</u>	<u>396,785</u>

Accounting policy for trade and other payables

These amounts represent liabilities for goods and services provided to the Group consisting of dorsaVi and the entities it controlled prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Note 9. Liabilities - provisions

	2025	2024
	\$	\$
Current employee benefits	236,905	181,724
Non-current employee benefits	4,590	8,608
	<u>241,495</u>	<u>190,332</u>

Accounting policy for employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Note 10. Current liabilities - other liabilities

	2025	2024
	\$	\$
Contract liabilities	<u>272,572</u>	<u>383,425</u>

DorsaVi Limited and controlled entities
Notes to the financial statements
30 June 2025

Note 11. Equity - issued capital

	2025 Shares	2024 Shares	2025 \$	2024 \$
Ordinary shares - fully paid	<u>841,196,963</u>	<u>615,177,534</u>	<u>50,584,213</u>	<u>47,288,516</u>

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2023	553,210,913		46,325,268
Employee incentive scheme	5 July 2023	3,450,705	-	-
Placement	9 November 2023	40,000,000	\$0.01	400,000
Placement	13 June 2024	10,000,000	\$0.01	100,000
Settlement of fees	13 June 2024	2,884,615	-	-
Exercise of options	13 June 2024	1,932,250	-	-
Employee incentive scheme	13 June 2024	2,599,051	-	71,283
Employee incentive scheme	13 June 2024	1,100,000	-	-
Transfer from share based payment reserve		-	-	421,965
Capital raising fees		-	-	(30,000)
Balance	30 June 2024	615,177,534		47,288,516
Placement	13 August 2024	50,000,000	\$0.011	550,000
Shares issued on conversion of vested performance rights	13 August 2024	1,153,846	\$0.011	-
Shares issued in settlement of consulting fees	14 August 2024	3,444,554	\$0.011	53,815
Placement	15 November 2024	50,000,000	\$0.011	550,000
Shares issued to Directors in lieu of fees payable	15 November 2024	11,461,991	\$0.011	126,082
Placement	27 June 2025	105,000,000	\$0.013	1,365,000
Shares issued on conversion of vested performance rights	27 June 2025	4,959,038	\$0.015	-
Money received - shares not yet issued		-	\$0.013	910,000
Capital raising fees		-	-	(259,200)
Balance	30 June 2025	<u>841,196,963</u>		<u>50,584,213</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Group consisting of dorsaVi and the entities it controlled in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Group consisting of dorsaVi and the entities it controlled does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Accounting policy for issued capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

DorsaVi Limited and controlled entities
Notes to the financial statements
30 June 2025

Note 12. Equity - reserves

	2025 \$	2024 \$
Foreign currency reserve	(807,211)	(782,906)
Share-based payments reserve	900,369	1,049,776
	<u>93,158</u>	<u>266,870</u>

(i) Nature and Purpose of Reserves

The share-based payment reserve is used to record the fair value of options and shares issued to employees as part of their remuneration. The balance is transferred to share capital when options are granted, and the balance is transferred to retained earnings when options lapse.

DorsaVi Ltd has monetary items receivable and payable to and from its subsidiaries. Under AASB 121: The Effects of Changes in Foreign Exchange Rates, these items are reviewed annually. These items are treated as an investment in those foreign operations. As a result, exchange differences on these items are recognised initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment.

(ii) Movements in reserves

Movements in each class of reserve during the current and previous financial year are set out below:

	Share-based payment reserve \$	Foreign currency translation reserve \$	Total \$
Balance at 1 July 2023	1,406,840	(768,996)	637,844
Employee share ownership plan	47,752	-	47,752
Other share-based payments	17,149	-	17,149
Transfer to issued capital	(421,965)	-	(421,965)
Exchange differences on translation of foreign operations	-	(13,910)	(13,910)
Balance at 30 June 2024	1,049,776	(782,906)	266,870
Employee share ownership plan	-	-	-
Other share-based payments	-	-	-
Transfer to issued capital	(67,415)	-	(67,415)
Exchange differences on translation of foreign operations	-	(24,305)	(24,305)
Expiry of options	(208,074)	-	(208,074)
Share based payments	126,082	-	126,082
Balance at 30 June 2025	<u>900,369</u>	<u>(807,211)</u>	<u>93,158</u>

Note 13. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Note 14. Events after the reporting period

On 4 July 2025, the Company issued the remaining 70,000,000 shares at \$0.013 (1.3 cents) raising \$910,000 before transaction costs.

DorsaVi Limited and controlled entities
Notes to the financial statements
30 June 2025

Note 14. Events after the reporting period (continued)

On 18 August 2025 the Company announced that it had received commitments for a Placement of \$5 million (before costs) to accelerate the development of the Company's RRAM and Robotics technology. A total of 125,000,000 shares will be issued with an issue price of \$0.04 (4 cents) per share through the Placement. The Company proposes to issue 125,000,000 in accordance with the Company's current placement capacity. The Company will also issue 62,500,000 free attaching unlisted options, on a 1 for 2 basis, with an exercise price of \$0.075 (7.5 cents) per option and expiring 3 years from the date of issue (**Options**). The issue of Options will be subject to shareholder approval.

On 28 August 2025 the Company announced that Mathew Regan has been appointed as Group Chief Executive Officer with an effective date of 1 November 2025. As part of Mathew's appointment, he will be issued a total of 24,000,000 performance rights with various vesting conditions and the issue of the performance rights will be subject to shareholder approval.

No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Group consisting of DorsaVi and the entities it controls, the results of those operations, or the Group consisting of DorsaVi and the entities it controls state of affairs in future financial years.

Note 15. Loss per share

	2025 \$	2024 \$
Loss after income tax attributable to the owners of DorsaVi Limited and controlled entities	<u>(1,517,753)</u>	<u>(1,247,582)</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>702,312,852</u>	<u>548,130,023</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>702,312,852</u>	<u>548,130,023</u>
	Cents	Cents
Basic earnings per share	(0.22)	(0.23)
Diluted earnings per share	(0.22)	(0.23)

Accounting policy for earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the owners of DorsaVi Limited and controlled entities, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.